Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VRTX - Vertex Pharmaceuticals, Inc.


IEX Last Trade
495.58
2.230   0.450%

Share volume: 1,809,551
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$493.35
2.23
0.45%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
46%
Profitability 67%
Dept financing 7%
Liquidity 62%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
3.04%
1 Month
-1.34%
3 Months
11.93%
6 Months
16.14%
1 Year
41.38%
2 Year
76.25%
Key data
Stock price
$495.58
P/E Ratio 
-261.26
DAY RANGE
N/A - N/A
EPS 
-$1.88
52 WEEK RANGE
$340.83 - $510.64
52 WEEK CHANGE
$0.41
MARKET CAP 
127.990 B
YIELD 
N/A
SHARES OUTSTANDING 
258.102 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
0.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,072,954
AVERAGE 30 VOLUME 
$1,193,568
Company detail
CEO: Reshma Kewalramani
Region: US
Website: https://www.vrtx.com/
Employees: 4,800
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.

Recent news